
Metabolic Dysfunction-Associated Steatohepatitis: The Global Epidemic Fueling a New Era in Liver Disease Innovation
MASH prevalence nears 500M globally. With the first FDA-approved drug now available, the market is poised for explosive growth through 2032. AUSTIN, TX, UNITED STATES, June 6, 2025 /EINPresswire.com/ -- Metabolic Dysfunction-Associated …